Ecopipam's D1 Receptor Approach Signals New Pediatric Neuroscience Pathway

On August 19,2026, the FDA accepted Teva Pharmaceuticals' New Drug Application (NDA) for ecopipam, an investigational treatment for pediatric patients with Tourette syndrome.¹ The application has been granted Priority Review along with Orphan Drug designation, and the agency has set a targeted action date for late in the first quarter of 2027.

Ecopipam is an investigational therapy designed to block dopamine signaling at the D1 receptor.¹ This mechanism addresses a specific hypothesis in Tourette syndrome pathology, that D1 receptor hypersensitivity may drive the repetitive and compulsive behaviors characteristic of the condition. If approved, ecopipam would represent the first new treatment option for pediatric Tourette syndrome patients in more than a decade, and the first therapy built on a novel mechanism of action in more than 50 years.

What Does the Clinical Evidence Show?

The NDA acceptance rests on data from phase 2b and phase 3 trials.¹ The phase 2b study enrolled 153 pediatric participants across 68 sites in North America and Europe in a 12-week randomized, double-blind, placebo-controlled design. Patients receiving ecopipam showed statistically significant and clinically meaningful reductions in tic severity compared to placebo at week 12. A subsequent open-label extension followed 121 of those participants for up to 12 months and supported the durability of that effect.

The phase 3 program took a randomized withdrawal approach: 216 pediatric and adult participants entered an open-label stabilization period, after which 104 responders were randomized to continue ecopipam or switch to placebo.¹ For the primary endpoint, pediatric responders on ecopipam had a 53% decreased risk of relapse over 12 weeks compared to placebo.

Across the phase 2b, open-label extension, and phase 3 studies, researchers reported no clinically meaningful changes in body weight, metabolic or laboratory parameters, cardiac measurements, movement-disorder scales, or psychiatric comorbidity measures.

What Did the Trial's Design Reveal About Ecopipam's Durability?

The phase 3 randomized clincal trial ecopipam was titrated to a target dose of 1.8 mg per kilogram per day.² Only participants who achieved at least a 25% improvement in the Yale Global Tic Severity Scale Total Tic Scoreby week 12 were randomized into the double-blind withdrawal phase, a design intended to isolate maintenance of effect from initial response.

Among pediatric participants, relapse occurred in 68.1% of those switched to placebo compared with 41.9% of those who continued ecopipam.² The most frequently reported adverse events were somnolence, anxiety, headache, insomnia, tic, and fatigue, and the trial recorded no clinically meaningful changes in body mass index, metabolic markers, or drug-induced movement measures. This safety profile is notable given that antipsychotics, currently the only approved Tourette syndrome medications, carry known risks of weight gain and movement-related side effects that often drive treatment discontinuation.

Why Does This Matter?

Tourette syndrome affects an estimated 100,000 children and adolescents in the United States, yet only about half receive prescription treatment, and just 20-30% remain on therapy after a year.¹ That gap reflects a long-standing reliance on medications developed for other indications, many of which carry tolerability limitations. An indication-specific therapy targeting an underserved pediatric population illustrates how orphan drug and priority review pathways continue to shape sponsors' regulatory and development strategies in areas of high unmet need.

Eric Hughes, MD, PhD, executive vice president, Global R&D and Chief Medical Officer, Teva, said in the press release,¹ “If approved, ecopipam would be the first new therapy for Tourette syndrome in more than 10 years and the first novel mechanism of action in more than 50 years, offering patients and families a long-awaited new treatment option.”

The FDA's targeted action date puts a potential approval decision in the first quarter of 2027, a milestone worth tracking for its implications on pediatric neuroscience development pathways more broadly.¹

References

1. US FDA accepts Teva’s new drug application and grants priority review for ecopipam, a first-in-class investigational therapy for pediatric patients with Tourette syndrome. News release. Teva Pharmaceuticals. August 19, 2026. https://www.tevapharm.com/
2. Gilbert DL, et al. Efficacy and safety of ecopipam for Tourette syndrome. JAMA Neurology. Published online August 19, 2026. doi:10.1001/jamaneurol.2026.3063